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Tumor and Stem Cell Biology
Bcl9/Bcl9l Are Critical for Wnt-Mediated Regulation of Stem
Cell Traits in Colon Epithelium and Adenocarcinomas
Jürgen Deka1,2, Norbert Wiedemann1, Pascale Anderle4, Fabienne Murphy-Seiler1, Jennyfer Bultinck1,
Sven Eyckerman1, Jean-Christophe Stehle3, Sylvie André1, Nathalie Vilain1, Olav Zilian1,
Sylvie Robine5, Mauro Delorenzi6, Konrad Basler7, and Michel Aguet1,2
Abstract
Canonical Wnt signaling plays a critical role in stem cell maintenance in epithelial homeostasis and carcinogen-
esis. Here, we show that in the mouse this role is critically mediated by Bcl9/Bcl9l, the mammalian homologues of
Legless, which in Drosophila is required for Armadillo/β-catenin signaling. Conditional ablation of Bcl9/Bcl9l in
the intestinal epithelium, where the essential role of Wnt signaling in epithelial homeostasis and stem cell main-
tenance is well documented, resulted in decreased expression of intestinal stem cell markers and impaired re-
generation of ulcerated colon epithelium. Adenocarcinomas with aberrant Wnt signaling arose with similar
incidence in wild-type and mutant mice. However, transcriptional profiles were vastly different: Whereas
wild-type tumors displayed characteristics of epithelial-mesenchymal transition (EMT) and stem cell–like prop-
erties, these properties were largely abrogated inmutant tumors. These findings reveal an essential role for Bcl9/
Bcl9l in regulating a subset of Wnt target genes involved in controlling EMT and stem cell–related features and
suggest that targeting the Bcl9/Bcl9l arm of Wnt signaling in Wnt-activated cancers might attenuate these traits,
which are associatedwith tumor invasion, metastasis, and resistance to therapy. Cancer Res; 70(16); 6619–28. ©2010AACR.
Introduction
Canonical Wnt signaling regulates critical processes dur-
ing embryonic development and adult tissue renewal, and
aberrant activation of this pathway is associated with colo-
rectal cancer and other cancers (1). Wnt-induced transcrip-
tional regulation is mediated through a complex of Lef1/Tcf
transcription factors and stabilized β-catenin that interacts
with numerous cofactors (2). This complex includes Legless
(Lgs; ref. 3), which tethers Pygopus to the most NH2-terminal
repeat of Armadillo (Arm)/β-catenin and in Drosophila is
required for the transcriptional activity of the complex (3, 4). In
mammalian cells, BCL9 proteins contribute to, but may not be
obligatory for, β-catenin–mediated transcription (5, 6). BCL9L
mRNA knockdown in a human colon cancer cell line induced
an epithelial phenotype that was associated with the transloca-
tion of β-catenin from the nucleus to the cell membrane, sug-
gesting that BCL9L might regulate the switch between the
adhesive and transcriptional functions of β-catenin (5).
BCL9L upregulation has been associated with breast (7) and
colon cancers (8–10), and BCL9 has recently been reported to en-
hance β-catenin–mediated transcription and increase the
proliferation as well as themetastatic potential of tumor cells (9).
To investigate the role of Bcl9 proteins in mice, we gener-
ated loxP alleles of the murine lgs orthologues, Bcl9 and Bcl9l,
which were crossed into transgenic strains expressing Cre re-
combinase either constitutively or inducibly under the con-
trol of the villin promoter (11). Thereby, deletion of Bcl9 and
Bcl9l was targeted selectively to the intestinal epithelium, for
which the essential role of Wnt signaling for epithelial ho-
meostasis is well documented (12).
Here, we report that ablation of Bcl9/Bcl9l in the intestinal
epithelium selectively abrogated the expression of a subset of
Wnt-regulated genes, which are critical for controlling stem
cell–like properties, both in normal colon epithelium and in a
colon adenocarcinoma model.
Materials and Methods
Generation of Bcl9−/−/Bcl9l−/− mice
For the generation of conditional Bcl9−/−/Bcl9l−/− mice, ex-
on V of Bcl9 and exons VI and VII of Bcl9l were flanked with
loxP sites in adjacent introns. Simultaneous deletion of both
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genes in the intestinal epithelium was achieved by crossing
with villin-Cre-ERT2 or villin-Cre transgenic mice, resulting in
vil-Cre-ERT2-Bcl9loxP/loxP/Bcl9lloxP/loxP (on tamoxifen induction:
vil-Cre-ERT2-Bcl9−/−/Bcl9l−/−) and vil-Cre-Bcl9−/−/Bcl9l−/− lines.
More detailed information is available in Supplementary
Materials and Methods.
Mouse experimentation
Mouse experiments were performed in accordance with
Swiss guidelines and approved by the Veterinarian Office of
Vaud, Switzerland. The protocols for gene ablation in vil-
Cre-ERT2-Bcl9loxP/loxP/Bcl9lloxP/loxP mice and the induction of
ulcerative colitis and colon chemical carcinogenesis are pro-
vided in Supplementary Materials and Methods.
Laser dissection microscopy
Samples of colon tissue were washed in chilled PBS, em-
bedded in optimal cutting temperature compound, and fro-
zen immediately. Frozen sections (14 μm) were mounted on
Leica membranes (Leica Microsystems) for laser dissection
microscopy, fixed in ethanol, and colored with Mayer's hema-
toxylin. Membranes were rinsed in water and ethanol and
air-dried. Samples were prepared using a laser-dissecting
microscope (MMI-Nikon, Leica Microsystems). Total RNA
(20 μL) was extracted using the PicoPure RNA Isolation Kit
(MDS Analytical Technologies).
Comparative gene expression analysis
RNA quality was assessed using the Agilent 2100 Bioanaly-
zer (Agilent Biotechnologies) and RNA was quantified with a
NanoDrop spectrophotometer (Witec AG). Total RNA (30 ng)
was amplified using the NuGEN WT-Ovation Pico kit and the
cDNA was hybridized to Affymetrix Mouse Genome 430 2.0
arrays. Robust multiarray averaging and quantile normaliza-
tion were used to quantify gene expression (R, Bioconductor,
RMA package). Significant differences were identified by ap-
plying a moderated t test approach (R, Bioconductor, LIMMA
package; ref. 13). The gene expression microarray data re-
ported herein were deposited in the Gene Expression Omni-
bus repository (accession no. GSE21603; see Supplementary
Data for details). If not indicated otherwise, a threshold of
an adjusted P ≤ 0.05 (Benjamini-Hochberg FDR correction)
was used to identify significant changes between wild-type
and mutant samples.
Genes with significantly different expression in wild-type
as compared with Bcl9−/−/Bcl9l−/− tumors were analyzed with
the functional annotation chart tool in DAVID (14). Gene on-
tology (GO) terms related to “biological processes” were
used. Fisher's exact test was applied to calculate significance.
Terms with an adjusted P < 0.05 (Benjamini-Hochberg FDR
correction) were defined as significant.
Gene set enrichment analysis (GSEA) was carried out ac-
cording to Subramanian and colleagues (15). P values were
computed using a bootstrap distribution created by resam-
pling gene sets of the same cardinality. This is a heuristic ap-
proach to identifying gene sets and biological functions that,
given the samples used, seem to be most related to the ob-
served effects. Its P values could overestimate the appropriate
level of confidence in relation to the extent of the biological
variability that was sampled and are better considered as com-
parative scores between gene sets. Lists of direct Wnt targets
(n = 24), genes involved in epithelial-mesenchymal transition
(EMT; n = 13), and genes enriched in intestinal stem cells
marked by the expression of Lgr5 were generated manually
(Fig. 4A). Heat maps were generated using Cluster 3.0 and
TreeView (ref. 16; http://rana.lbl.gov/EisenSoftware.htm). As
a similarity measurement and clustering method, centered
correlation and average linkage clustering, respectively, were
applied. The Davies-Bouldin index was determined as de-
scribed (17), whereby intercluster and intracluster differences
were calculated using the average of all pairwise comparisons.
The Davies-Bouldin index is a ratio that compares the average
distance within a group of samples to that between groups. A
value of 2 indicates no difference and smaller values indicate
better discrimination with a theoretical minimum of 0. All
configurations tested were obtained by cutting the hierarchi-
cal tree into two clusters that always corresponded to the five
mutant and the five wild-type samples.
The significance of quantitative real-time PCR (qRT-PCR)
data was determined using Student's t test (P ≤ 0.05).
Standard protocols and reagents
Quantitative RT-PCR, in situ hybridization, and immuno-
histochemistry were carried out according to standard pro-
tocols. Details and reagents are provided in Supplementary
Materials and Methods.
Results
Ablation of Bcl9/Bcl9l results in decreased intestinal
stem cell marker expression and impaired
epithelial regeneration
Despite the rather low overall sequence identity, mouse
Bcl9 and Bcl9l share seven highly conserved domains (18),
suggesting that they might be functionally redundant. As
both genes were expressed in the small intestine and colon,
with Bcl9 generally expressed at an approximately 2- to
4-fold higher level than Bcl9l (data not shown), all loss-of-
function experiments presented herein were carried out on
a compound Bcl9/Bcl9l mutant background. Conditional
loss-of-function alleles of Bcl9 and Bcl9l (GenBank accession
nos. AY296061 and AY296058) were generated by flanking
exons encoding the functionally essential β-catenin interac-
tion domain with loxP sites (Supplementary Fig. S1A). Mouse
strains with compound inducible or constitutive deletion of
both genes confined to the intestinal epithelium were ob-
tained through crossing with villin-Cre-ERT2 or villin-Cre
transgenic mice, respectively (11), resulting in vil-Cre-ERT2-
Bcl9loxP/loxP/Bcl9lloxP/loxP (on tamoxifen induction: vil-Cre-
ERT2-Bcl9−/−/Bcl9l−/−) and vil-Cre-Bcl9−/−/Bcl9l−/− lines. Unless
stated otherwise, experiments reported herein were carried
out initially on a villin-Cre-ERT2 background and reproduced
using the constitutive villin-Cre transgene. Bcl9loxP/loxP/
Bcl9lloxP/loxP littermates lacking the Cre transgene served
as controls.
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Deletion of Bcl9/Bcl9l proved highly efficient in both
strains (Supplementary Fig. S1B–D). Induced ablation of
Bcl9/Bcl9l in the villin-Cre-ERT2 strain assessed 23 weeks af-
ter tamoxifen administration proved similarly efficient as in
mice with constitutively active Cre, suggesting that the dele-
tion was unaffected by epithelial renewal and therefore had
encompassed the epithelial progenitor cell compartment.
Neither induced nor constitutive ablation of Bcl9/Bcl9l in
the intestinal epithelium resulted in any overt anomalies, and
all intestine-specific cell lineages were equally present in
mutant and control mice (Supplementary Fig. S2).
Canonical Wnt signaling as revealed by expression of the
direct target gene Axin2 (19) did not seem to be significantly
altered in small intestinal epithelium and was only mildly
reduced in the colon epithelium of mutant mice (Supplemen-
tary Fig. S1D). To assess Wnt signaling more comprehen-
sively, EDTA-dissociated colon epithelial cells (20) from
three pools each of wild-type and Bcl9/Bcl9l–mutant mice
were subjected to an exploratory comparative gene expres-
sion profiling. Using an adjusted P < 0.05 as a threshold
(see Materials and Methods), no significant gene expression
changes were observed between wild-type and mutant colon
epithelium. Notably, Wnt target gene expression (http://
www.stanford.edu/~rnusse/wntwindow.html) did not prove
to be significantly affected in Bcl9/Bcl9l–mutant colon epi-
thelium, strikingly, with the exception of the intestinal stem
cell marker Lgr5 (21), which was reduced 3.4-fold (P = 2E−5,
not adjusted for multiple testing). A GSEA (15) was therefore
carried out with a recently reported set of genes with ≥2-fold
enriched expression in Lgr5-positive stem cells isolated from
the small intestine (22); results revealed a weak but signifi-
cant enrichment in wild-type versus Bcl9/Bcl9l–mutant colon
epithelium (P = 0.019). The expression of genes enriched in
this analysis was further assessed by qRT-PCR (Fig. 1A).
Expression of the other genes coexpressed selectively in
Lgr5-positive small intestine stem cells was significantly
Figure 1. Reduced intestinal stem cell marker expression and impaired regeneration of Bcl9−/−/Bcl9l−/− epithelium. A, quantification by qRT-PCR in
colon epithelium of genes with enriched expression in small intestine stem cells (22). Only genes with significantly reduced expression in Bcl9−/−/Bcl9l−/−
compared with wild-type epithelium are shown (n = 7 ± SE for wild-type epithelium; n = 6 ± SE for Bcl9−/−/Bcl9l−/− epithelium; P ≤ 0.05). B, percentages
of wild-type and Bcl9−/−/Bcl9l−/− mice with >20% weight loss after treatment with DSS (n = 30, P = 0.00095 for vil-Cre-ERT2-Bcl9−/−/Bcl9l−/− mice; n = 28,
P = 0.00136 for vil-Cre-Bcl9−/−/Bcl9l−/− mice). C, H&E staining and analysis of Axin2 expression by in situ hybridization on sections of mouse colon
showing representative DSS-induced lesions 6 d after DSS administration was terminated. Bar, 150 μm.
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diminished in the absence of Bcl9/Bcl9l. Interestingly, expres-
sion of achaete scute-like 2 (Ascl2), which has recently been
reported to control intestinal stem cell fate (22), did not
prove to be significantly different between wild-type and mu-
tant colon epithelium (Supplementary Fig. S4).
To investigate the regenerative capacity of Bcl9−/−/Bcl9l−/−
intestinal epithelium, mice were challenged by p.o. adminis-
tration for 7 days of the irritant dextran sulfate sodium (DSS),
which has been described to provoke severe colitis with ex-
tensive ulcerations (23). Animals were monitored for weight
loss and sacrificed when the loss reached 20% (Fig. 1B).
Whereas the majority of control mice recovered 5 to 7 days
after DSS administration was discontinued and had lost less
than 20% body weight, the majority of mutant mice crossed
the 20% weight loss percentile. At this stage, mutant mice
showed considerably more extended ulcerative lesions within
the colon epithelium. Whereas control lesions underwent
visible re-epithelialization with the formation of new crypts
at wound borders, the large open wounds of mutant mice
displayed no evidence of ongoing epithelial regeneration
(Fig. 1C). Like in mutant colon epithelium, Axin2 expression
seemed slightly reduced at mutant wound borders, this dif-
ference did not prove to be significant, however, when quan-
tified by qRT-PCR (data not shown). Thus, ablation of Bcl9/
Bcl9l resulted in reduced expression of intestinal stem cell
markers in Bcl9/Bcl9l–mutant colon epithelium and was
associated with impaired epithelial regeneration capacity.
Bcl9−/−/Bcl9l−/− adenocarcinomas show impaired
expression of selected Wnt target genes
To investigate the effect of Bcl9/Bcl9l ablation on tumori-
genesis, 6- to 8-week-old mice were exposed first to a single
dose of dimethylhydrazine, which is metabolized in the liver
to carcinogenic azoxymethane, followed by 7 days of p.o. ad-
ministration of DSS in the drinking water. This regimen re-
sults in the emergence of dysplastic adenomas, which
progress to differentiated adenocarcinomas that are morpho-
logically similar to human colorectal adenocarcinoma and
typically harbor β-catenin–stabilizing mutations of glycogen
synthase kinase-3β phosphorylation sites (24). Accordingly,
these tumors presented hallmarks of active Wnt signaling
such as accumulation of nuclear β-catenin and expression
of Wnt target genes (Fig. 2).
Vil-Cre-ERT2-Bcl9−/−/Bcl9l−/− and vil-Cre-Bcl9−/−/Bcl9l−/−
mice developed tumors in the distal colon at a slightly higher
frequency than their littermate controls (not reproducibly
significant; Fig. 2A). Tumors from mutant mice were gener-
ally of smaller size (mean tumor diameter: wild-type tumors,
4.4 ± 1.7 mm, n = 58; Bcl9−/−/Bcl9l−/− tumors, 2.4 ± 1.0 mm, n =
110; two-sample t test P = 5.1E−12). Bromodeoxyuridine in-
corporation, however, did not prove to be significantly differ-
ent (data not shown). To rule out that tumors emerged from
residual wild-type epithelial cells in otherwise mutant epithe-
lium, cDNA was obtained from laser capture microdissected
tumor samples, and expression of wild-type Bcl9 and Bcl9l
transcripts assessed by qRT-PCR (Fig. 2B). The residual level
of wild-type transcripts in tumors from mutant mice was
incompatible with heterozygous escaper tumor cells and
likely due to stromal components. Wild-type and mutant tu-
mors presented as exophytic, low-grade adenocarcinomas
(Fig. 2C) and were indistinguishable on H&E staining.
Nuclear accumulation of β-catenin was indicative of Wnt
pathway activation and expression of Axin2 provided evi-
dence for Wnt signaling activity, both in wild-type and mu-
tant tumors, whereby Axin2 expression seemed to be reduced
in the absence of Bcl9/Bcl9l (Fig. 2C).
To assess at a genome-wide level to what extent loss of
Bcl9/Bcl9l function affected gene expression, individual
cRNA probes were prepared from microdissected tumor
epithelium of five randomly chosen tumors (two wild-type
and three vil-Cre-Bcl9−/−/Bcl9l−/− littermates) and sub-
jected to comparative gene expression profiling. Despite
the close morphologic resemblance, transcriptomes from
Bcl9−/−/Bcl9l−/− tumors proved vastly different from wild-
type tumors.
Unsupervised hierarchical clustering with all probe sets
formed two well-separated clusters according to the geno-
types (Fig. 3A). Based on adjusted P ≤ 0.05 as a threshold
(see Materials and Methods), 746 genes were expressed at
a higher level and 946 at a lower level in wild-type than in
Bcl9−/−/Bcl9l−/− tumors (Supplementary Table S1). Analysis
of GO terms contained within the domain “biological
processes” (14) sorted according to their overrepresentation
(P < 0.05) revealed a marked enrichment in wild-type tumors
of processes relating to development (Supplementary
Table S2). GO terms relating to Wnt signaling were the only
pathway-associated terms enriched in wild-type samples.
In Bcl9−/−/Bcl9l−/− tumor samples, GO terms related to im-
mune response were predominantly enriched (Supplemen-
tary Table S2), mainly due to the higher expression of
epithelial chemokines and genes expressed in T and B cells
(Supplementary Table S1). Preliminary evidence obtained
from microdissected normal colon epithelium indicated that
expression of chemoattractants in mutant tumor samples
was closer to that of wild-type or mutant epithelium than
to that of wild-type tumors (data not shown).
To assess to what extent canonical Wnt signaling was af-
fected in Bcl9/Bcl9l–mutant tumors, a set of 24 Wnt target
genes relevant to human colon and/or other cancers, with
a proven direct transcriptional control through TCF binding
sites, was assembled from the Wnt home page and published
reports [http://www.stanford.edu/~rnusse/wntwindow.html;
Apcdd1 (ref. 25), Prox1 (ref. 26), Vim (ref. 27), S100a4
(ref. 28), Fscn1 (ref. 29), and T (ref. 30)]. This set was used
for hierarchical clustering and GSEA (Fig. 3B) and revealed
a significantly enriched expression in wild-type compared
with Bcl9−/−/Bcl9l−/− tumors (P = 4.3E−05). Accordingly, inter-
cluster separation assessed by the Davies-Bouldin index (17)
proved stronger with this 24 Wnt target gene set than with
the set of the 24 genes varying the most across all samples.
These data unequivocally showed the relatedness of Bcl9/
Bcl9l to the Wnt pathway. A subset of the Wnt target genes
was downregulated in Bcl9−/−/Bcl9l−/− tumors as compared
with wild-type tumors (Fig. 3B). The expression of all 24
genes contained in the Wnt target gene set was verified by
qRT-PCR (Fig. 3C).
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Bcl9−/−/Bcl9l−/− adenocarcinomas show reduced
expression of EMT and stem cell–associated markers
The subset of Wnt target genes with reduced expression in
Bcl9−/−/Bcl9l−/− tumors included genes relating to mesenchy-
mal phenotypes [vimentin (31); T (brachyury; ref. 30)]. To ad-
dress to what extent the processes relating to EMT, known to
be mediated in part by Wnt signaling (32), were more gener-
ally affected in the absence of Bcl9/Bcl9l, a set of 13 genes
described to relate to EMT was assembled (32, 33). Clustering
the tumor samples with this set revealed a stronger separa-
tion between the two genotype clusters than using the 13
genes varying the most across all samples (Fig. 3B). Verifica-
tion by qRT-PCR confirmed that a number of EMT-inducing
transcription factors present in wild-type tumors were in
part strongly downregulated in Bcl9−/−/Bcl9l−/− tumors,
consistent with the marked reduction of the mesenchymal
marker proteins vimentin, T (brachyury), and fibronectin
1 (Fig. 3C).
Recent evidence suggests that EMT may be associated
with the induction of stem cell–like properties (32, 34). A
GSEA was therefore carried out with the same set of 50 genes
with ≥2-fold enriched expression in Lgr5-positive intestinal
stem cells that was previously used to probe the transcrip-
tomes of wild-type and Bcl9−/−/Bcl9l−/− colon epithelium
(ref. 22; Fig. 1A). This analysis revealed a highly significant
enrichment for expression of this gene set in the wild-type
Figure 2. Bcl9−/−/Bcl9l−/− mice develop colon tumors with hallmarks of active Wnt signaling. A, number of tumors that developed in Bcl9−/−/Bcl9l−/−
mice and littermate controls. Results from two independent experiments are shown that were carried out with either vil-Cre-ERT2- Bcl9−/−/Bcl9l−/− or
vil-Cre- Bcl9−/−/Bcl9l−/− mice. Mice were sacrificed 20 or 25 wk, respectively, after exposure to dimethylhydrazine. B, Bcl9 and Bcl9l transcript levels in
dimethylhydrazine/DSS–induced colon tumors and adjacent normal colon epithelium were determined by qRT-PCR using total RNA extracted from
microdissected tumor tissue (nontumorous epithelium, n = 5 ± SE; wild-type tumor tissue, n = 3 ± SE; mutant tumor tissue, n = 8 ± SE). Expression levels in
normal epithelium were set to 100%. C, tumor morphology and expression of Bcl9 and the Wnt signaling markers β-catenin and Axin2. Bars, 150 μm.
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tumor samples (P = 1E−6), and accordingly, intercluster
separation was superior to the separation observed with
the control set of 50 genes varying the most across all sam-
ples (Fig. 3B). Expression of genes contained in this stem
cell–associated gene set that were ≥2-fold decreased in mu-
tant tumors was validated by qRT-PCR (Fig. 3C).
For selected genes, expression differences between wild-
type and Bcl9−/−/Bcl9l−/− tumor samples were confirmed by
immunohistochemistry. Vimentin, whose expression can
be directly regulated by β-catenin/Tcf (27), is one of the
most reliable mesenchymal markers. The difference in vi-
mentin expression in wild-type compared with Bcl9−/−/
Bcl9l−/− tumors, however, was clearly attributed to its loss
in mutant epithelial cells (Fig. 4A, c versus d, e versus f)
and not to a lower stroma content. Higher magnification
revealed that wild-type tumor cells typically expressed api-
cal cytokeratin and basal vimentin intermediate filaments
(Fig. 4A, g). This coexistence of epithelial and mesenchy-
mal traits is characteristic of a metastable state in between
the epithelial and mesenchymal extremes (31). In contrast,
the vast majority of mutant tumor epithelium was consti-
tuted of vimentin-negative cells, which stained homoge-
neously for cytokeratin and EpCAM, indicative of a more
epithelial state (Fig. 4A, h).
To investigate to what extent stem cell marker ex-
pression might coincide with this metastable cell state,
expression of Sox6, the only differentially expressed
Lgr5-associated marker amenable to immunohistochemis-
try, was visualized. In wild-type tumors, Sox6 expression
was confined to areas of strongest vimentin staining,
whereas it was hardly detectable in mutant tumors (Fig. 4B,
a versus b).
EMT occurs during development and marks a key step in
tumor progression toward metastasis (33). An initial step
during EMT, when epithelial cells acquire mesenchymal
traits and become more motile, is the breakdown of the base-
ment membrane (35). Immunohistochemical staining of the
basement membrane component laminin in wild-type and
Bcl9/Bcl9l–mutant colon tumors was consistent with the
EMT state of wild-type tumors. Thus, virtually no basement
membrane laminin was observed in vimentin-positive wild-
type tumor epithelium (Fig. 4B, c). In contrast, the epithelium
in Bcl9−/−/Bcl9l−/− tumors seemed to be aligned on a contig-
uous intact laminin membrane (Fig. 4B, d). Concordant ob-
servations were made with immunohistochemical staining of
collagen IV (data not shown).
Recently, the Prox1 homeobox transcription factor was
associated with the acquisition of malignant traits in a sim-
ilar mouse colon carcinoma model and shown to be directly
regulated by β-catenin/Tcf signaling in colorectal cancer
(26). The marked difference in Prox1 expression between
wild-type and Bcl9−/−/Bcl9l−/− adenocarcinomas (Fig. 3C)
was confirmed by immunohistochemical staining (Fig. 4B,
e versus f), showing that Prox1 protein expression was
largely confined to vimentin-expressing cells and, like vi-
mentin, was expressed only in rare small foci of mutant ep-
ithelium (Fig. 4B, g versus h). It is noteworthy that this
concomitant expression of vimentin and Prox1 could be ob-
served already in small wild-type tumor lesions but was
barely discernible in similar-stage lesions of mutant mice
(Supplementary Fig. S3).
Collectively, these findings show that in this tumor
model, Bcl9/Bcl9l control a subset of direct Wnt target
genes that are involved in the regulation of EMT and stem
cell traits.
Discussion
In Drosophila, Lgs loss-of-function alleles resulted in phe-
notypes characteristic of reduced Wnt pathway activity (3).
In the mouse, within the context of the adult intestinal epi-
thelium, ablating the Lgs homologues Bcl9/Bcl9l did not
cause anomalies reminiscent of other mouse Wnt pathway
mutants, which typically resulted in reduced epithelial prolif-
eration and loss of crypts (36–39). Analysis of Bcl9/Bcl9l–
mutant colon epithelial cells, however, revealed a marked
reduction of markers associated with intestinal stem cells
and regulated in part by Wnt signaling (ref. 22; Fig. 1A).
The absence of any noticeable effect on epithelial homeosta-
sis, the unaltered expression of the stem cell specifying tran-
scription factor Ascl2 (ref. 22; Supplementary Fig. S4), and
the similar incidence of chemically induced colon adenocar-
cinomas (Fig. 2A), which are likely derived from crypt stem
cells (40), suggested that specification of intestinal stem cells
was largely unaltered in the absence of Bcl9/Bcl9l. The re-
duced expression of stem cell markers associated with the re-
generative deficiency observed in an ulcerative colitis model
(Fig. 1) suggested, however, that their function was impaired.
A relationship between Bcl9/Bcl9l and Wnt-mediated
regulation of stem cell traits was further revealed when
Wnt target gene expression was comprehensively as-
sessed in a mouse chemical carcinogenesis model of colon
Figure 3. Comparative gene expression profiling in chemically induced wild-type versus Bcl9/Bcl9l–mutant adenocarcinomas. A, unsupervised hierarchical
clustering of gene expression profiles from microdissected tumor epithelium of five randomly chosen tumors (two wild-type and three Bcl9/Bcl9l–
mutant mice) using all gene probe sets. The dendrogram shows a clear separation of the two genotypes. B, unsupervised hierarchichal clustering using a
set of direct Wnt target genes (n = 24), genes involved in EMT (n = 13), and genes with ≥2-fold enriched expression in Lgr5-positive stem cells isolated
from the small intestine (n = 50, ref. 22). WT, wild-type mice; KO, vil-Cre-Bcl9−/−/Bcl9l−/− mice. Heat maps indicate relative differences between single
samples and average expression (log 2 scale). DBI, Davies-Bouldin index for intercluster separation (17). Sets of Wnt-, EMT-, and intestinal stem cell–related
genes were compared with sets of the same size containing the genes with the highest variation across all samples (DBI in square brackets). A lower
DBI value indicates a better intercluster separation (see Materials and Methods). C, expression of Wnt target genes listed in B assessed by qRT-PCR
(n = 5 ± SE; P ≤ 0.05, except for *, P > 0.05); expression of EMT-related genes listed in B assessed by qRT-PCR (n = 5 ± SE; P ≤ 0.05, except for *, P > 0.05);
expression assessed by qRT-PCR of genes contained within the set enriched ≥2-fold in Lgr5-positive intestinal stem cells (22). For intestinal stem
cell–related genes, only genes with significantly reduced expression in Bcl9−/−/Bcl9l−/− compared with wild-type tumors are shown (n = 5 ± SE;
P ≤ 0.05). qRT-PCR validations were carried out with cDNA from the same tumor sections as in B.
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adenocarcinoma. Transcriptional profiles analyzed with a set
of direct Wnt target genes unequivocally distinguished wild-
type and Bcl9/Bcl9l–mutant tumors. However, the highly
significant intercluster separation proved to be due to the
downregulation of only some direct Wnt target genes in
Bcl9/Bcl9l–mutant tumors (Fig. 3B). This subset contained
genes that are associated with a mesenchymal phenotype
[T (brachyury; ref. 30); vimentin (31)], intestinal stem cells
(Lgr5; ref. 21), or colon cancer progression (Prox1; ref. 26).
In addition to Wnt-regulated mesenchymal markers, the ex-
pression of genes characteristic of EMT, including Foxc2,
which promotes mesenchymal differentiation during EMT
(41), Hmga2, which regulates expression of Snai1 (42), and
other EMT transcription factors including Snai2, Twist1,
Zeb1/2, as well as the matrix glycoprotein fibronectin, was
downregulated in mutant tumors (Fig. 3C). EMT has recently
been associated with the generation of cancer cells with stem
cell–like properties (34, 43). Strikingly, like in colon epitheli-
um, a gene signature associated with Lgr5-positive intestinal
stem cells (22) was strongly attenuated in Bcl9/Bcl9l–mutant
tumors and clearly distinguished wild-type from Bcl9/Bcl9l–
mutant tumors (Fig. 3B). Collectively, these observations in-
dicated that Bcl9/Bcl9l are critical for regulating a subset of
Wnt target genes relevant to controlling EMT- and stem cell–
associated traits. In contrast, Wnt-mediated transduction of
proliferative signals remained by and large unaffected by the
lack of Bcl9/Bcl9l.
In Drosophila, Lgs (Bcl9/Bcl9l) acts as a linker to recruit
Pygo to the Arm (β-catenin) complex (3). Pygo is an essential
transcriptional coactivator of this complex and has been sug-
gested to exert its function through binding to histone H3
tails and histone decoding (44). Recently, Pygo2 has been
Figure 4. Bcl9/Bcl9l are critical for maintaining colon adenocarcinoma cells in a metastable state characterized by coexpression of epithelial and
mesenchymal traits. A, H&E (a, b) and double immunofluorescence staining of wild-type and Bcl9−/−/Bcl9l−/− colon tumors for vimentin/EpCAM (green/red;
c, d, e, f) and vimentin/cytokeratin (green/red; g, h). B, immunofluorescence staining of wild-type and Bcl9−/−/Bcl9l−/− colon tumors for vimentin/Sox6 (green/red;
a, b), vimentin/laminin (green/red; c, d), and vimentin/Prox1 [green/red; DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI; blue fluorescence);
e, f, g, h]. Bar, 25 μm. Histologic analyses were carried out on a set of wild-type and vil-Cre-Bcl9−/−/Bcl9l−/− colon tumors different from those used in Fig. 3.
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reported to control Wnt signaling–dependent expansion of
mouse mammary progenitor cells (45). These findings are
in line with our observations and suggest a more general role
for Bcl9/Bcl9l and Pygo proteins in regulating stem cell–
relevant Wnt target gene expression, possibly by maintaining
chromatin in a permissive state (2).
Our observations on the role of Bcl9/Bcl9l may prove clin-
ically relevant. EMT is implicated in tumor invasion and me-
tastasis (33). There is growing evidence suggesting that
certain chemotherapy-resistant tumor cells display EMT
traits and stem cell properties (32, 46–48). In addition to
the lack of EMT features and the loss of stem cell–like prop-
erties, Bcl9/Bcl9l–mutant tumors showed reduced expression
of Wnt-regulated genes that have been directly associated
with malignant tumor traits. Thus, Prox1 has been implicat-
ed in malignant progression of colon adenocarcinoma, and
deletion of Prox1 in intestinal adenomas resulted in pheno-
typic changes similar to those described herein, such as the
preservation of well-organized basement membranes around
Prox1-deleted adenomas (26). It is therefore likely that some
of the phenotypic changes caused by the loss of Bcl9/Bcl9l
may be due to the downregulation of Prox1. Two other
Bcl9/Bcl9l–dependent, direct Wnt target genes, Fascin1
(29), a key component of filopodia, and Lef1 (49), have been
associated with tumor invasion and metastasis in colon or
lung cancer. Expression of Bambi, a newly described Wnt-
regulated and Bcl9l-dependent transforming growth factor-
β inhibitor, predictive of metastatic potential (50), also
proved significantly downregulated in Bcl9/Bcl9l–mutant ver-
sus wild-type adenocarcinomas (33.6% of mRNA expression
in wild-type tumors; n = 5; P = 0.015). The colon adenocarci-
noma model explored herein did not allow assessment of tu-
mor invasiveness and dissemination due to locally advanced
growth and precocious intestinal obstruction. Recently, how-
ever, RNA interference–mediated silencing of Bcl9 expression
in a colon cancer cell line was reported to significantly
reduce its metastatic potential (9). Collectively, the virtual
abrogation in the absence of Bcl9/Bcl9l of numerous traits
associated with malignant tumor progression strongly sug-
gests that targeting Bcl9/Bcl9l function in colon cancers
may result in attenuated malignancy, through reduction of
their propensity to disseminate and through inhibition of
stem cell–associated features, which may restore responsive-
ness to therapy (32).
These first time observations in loss-of-function mouse
mutants indicate that Bcl9/Bcl9l control a subset of Wnt-
regulated genes implicated in stem cell control. They warrant
further studies to investigate underlying mechanisms in-
volved in selective Wnt target gene regulation as well as to
explore the Bcl9/Bcl9l–regulated Wnt subprogram with a
view to therapeutically target stem cell–like traits in colon
and other Wnt-activated cancers.
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